Semaglutide dosing is not a single fixed amount — it follows a titration protocol in which the dose is increased gradually over several months. This approach was established through clinical…
One of the most significant concerns about GLP-1 receptor agonist use is the potential for loss of muscle mass alongside fat loss. This concern is scientifically legitimate — any substantial caloric deficit, regardless of how it is induced, results in some lean mass loss alongside fat loss. The relevant questions are: how much lean mass is lost with GLP-1R agonists specifically, how does this compare to other weight loss methods, and what can be done to minimise it.
One of the most frequently asked questions about GLP-1 receptor agonist peptides is how quickly they produce noticeable effects. The answer varies significantly depending on which effect you’re asking about…
GLP-1 receptor agonists have an established and generally well-characterised side effect profile. The most frequently reported effects are gastrointestinal in nature — nausea, vomiting, diarrhoea, and constipation — and are…
The landscape of GLP-1-based peptides has evolved rapidly. Where semaglutide established the clinical value of sustained GLP-1 receptor agonism, tirzepatide added GIP receptor co-activation, and retatrutide has extended the approach further to include the glucagon receptor. Each addition changes not just the potency but the character of the metabolic response. This article examines all three side by side.
Retatrutide — referred to in some research contexts as GLP-3, reflecting its triple receptor mechanism — is a synthetic peptide designed to activate three distinct G protein-coupled receptors simultaneously: the…
Semaglutide is a GLP-1 receptor agonist that shares approximately 94% sequence homology with native human GLP-1 — meaning its amino acid sequence is nearly identical to the body’s own hormone.…
Glucagon-like peptide-1 — commonly referred to as GLP-1 — is a peptide hormone produced in the gut in response to food intake. It belongs to the incretin family of hormones,…